ArticleTechnical innovations & patient support in radiation oncology2025
Bridging the proton gap: A proton therapy consultation service for Canadian radiation oncologists.
Article in Technical innovations & patient support in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Canada is the only G7 country without a clinical proton beam therapy (PBT) facility. Patients can access publicly funded PBT through provincial out-of-country approval programs. We created a consultation service to inform health care providers regarding the potential dosimetric benefits of PBT. Materials and Methods: We retrospectively reviewed patients referred to our proton consultation service from June 2020 to December 2024. Pencil beam scanning proton plans were generated in the RayStation treatment planning system. Key dosimetric parameters were evaluated using Wilcoxon matched-pairs signed rank test. Results: A total of 55 patients were referred to our service, and 49 had evaluable plans. Patients were referred from 6 provinces and 11 institutions across Canada. The median age at referral was 36 (range, 3-74 years), and 29 % of patients were pediatric. The most common reasons for referral were young age (33 %) and proximity of tumour to OARs (37 %). Target coverage was similar in both photon and proton plans. Cranial (n = 19) and thoracic (n = 7) plans showed a statistically significant reduction in mean brain dose (p < 0.001), mean brain dose minus PTV (p < 0.001), brain D50% (p < 0.001), mean lung dose (p = 0.02), lung V50% (p = 0.02), and lung D50% (p = 0.02) with proton therapy. Sixteen patients were approved by their provincial Ministry of Health for PBT in the United States. Conclusion: Our proton consultation program provides an important service by identifying patients where PBT offers a dosimetric advantage over photon therapy. Following this personalized, data-informed approach, nearly a third of referred patients were approved to go to the US for PBT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.